Adverse Reactions In Patients Research Articles

Role of D2 receptor (–141 C Ins/Del) genetic polymorphism on olanzapine-induced adverse drug reaction in schizophrenic patients

Olanzapine is commonly prescribed for the management of schizophrenia and is associated with many adverse effects like weight gain, hyperglycemia, and hyperprolactinemia, which may increase the risk of other diseases like diabetes mellitus and cardiovascular diseases. Genetic polymorphism of the D2 receptor may be responsible for the incidence of such adverse effects. This study aimed to assess the role of D2 receptor–141 C Ins/Del (rs1799732) genetic polymorphism and olanzapine-induced adverse effects in Iraqi schizophrenic patients. The case-control study was performed from October 2022 to April 2023 in Al-Hassan Al-Mojtaba Hospital. A total of 100 schizophrenic patients consisting of both genders, aged between 20 and 65 years, were recruited from the Psychiatry Outpatient Department, and 50 apparently healthy without any disease comprising both genders aged 20 to 63 years, served as a control group and were also enrolled in this study. Plasma level of FBS, HbA1c, lipid profile, and prolactin were measured, and genotyping of D2 Receptor–141 C Ins/Del (rs1799732) Polymorphisms was detected using the RFLP method. The heterozygous (Ins/Del) and mutant (Del/Del) alleles of D2 receptor–141 C Ins/Del (rs1799732) was significantly predominated in schizophrenic patient and absent in healthy volunteers. Schizophrenic patients with the deletion allele of D2 receptor–141 C Ins/Del and who were administered olanzapine (rs1799732) exhibited notably higher susceptibility to metabolic adverse effects induced by olanzapine, such as weight gain, hyperglycemia, dyslipidemia, and hyperprolactinemia. In conclusion, the genetic polymorphism of D2 receptor–141 C Ins/Del (rs1799732) was significantly associated with olanzapine induce metabolic adverse effects in Iraqi schizophrenic patients.

Correlation between gene polymorphism and adverse reactions of high-dose methotrexate in osteosarcoma patients: a systematic review and meta-analysis

ObjectiveWe aimed to provide a reference based on evidence for an individualized clinical medication of high-dose methotrexate (HD-MTX) in osteosarcoma patients by evaluating the effect of gene polymorphism on adverse reactions of HD-MTX usage.MethodsSeveral databases were combed for research on the association between gene polymorphisms and adverse reactions to HD-MTX up to January 2023. A meta-analysis and/or descriptive analysis on the incidence of HD-MTX-related adverse reactions were conducted by using clinical studies meeting inclusion criteria.ResultsTwelve studies involving 889 patients were included. There were 8, 6, 5, and 4 studies related to MTHFR C677T, MTHFR A1298C, RFC1 G80A, and MDR1 C3435T polymorphisms, respectively. The results of the meta-analysis showed that the MTHFR C677T polymorphism was associated with G3-4 hepatotoxicity, G3-4 nephrotoxicity, G3-4 gastrointestinal toxicity, and G3-4 mucositis under the recessive genetic model (MM vs. Mm/mm). Limited research showed that MTHFR C677T was associated with G3-4 nephrotoxicity in the allelic genetic model (M vs. m). MTHFR A1298C polymorphism was associated with a decreased risk of adverse reactions to HD-MTX usage, without statistical significance. This review's descriptive analysis showed no significant correlation between the RFC1 G80A, and MDR1 C3435T polymorphism and adverse reactions of HD-MTX.ConclusionThe MTHFR C677T mutation may enhance the risk of HD-MTX adverse reactions in osteosarcoma patients. Existing studies have not found a significant correlation between the MTHFR A1298C, RFC1 G80A, and MDR1 C3435T polymorphism and adverse reactions caused by HD-MTX. Lastly, this conclusion was limited because of few studies.

Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis.

Mastocytosis is a myeloproliferative neoplasm characterized by abnormal proliferation and activation of clonal mast cells typically bearing the KITD816V mutation. Symptoms manifest due to the release of bioactive mediators and the tissue infiltration by neoplastic mast cells. Mast cell activation symptoms include flushing, pruritus, urticaria, abdominal cramping, diarrhea, wheezing, neuropsychiatric symptoms, and anaphylaxis. Up to 50% of patients with mastocytosis report a history of provoked and unprovoked anaphylaxis, with Hymenoptera venom and drugs the most common culprits. NSAIDs, antibiotics, vaccines, perioperative medications, and radiocontrast media are often empirically avoided without evidence of reactions, depriving patients of needed medications and placing them at risk for unfavorable outcomes. The purpose of this review is to highlight the most common agents responsible for adverse drug reactions in patients with mastocytosis, with a review of current epidemiology, diagnosis, and management of drug hypersensitivity and Hymenoptera venom allergy.

Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.

Imatinib is the first-line treatment for gastrointestinal stromal tumors; however, the clinical prognosis and adverse reactions of patients vary owing to individualized discrepancies in plasma exposure. To determine the safe interval for steady-state plasma trough concentrations (C min ) of imatinib and its active metabolite, N-demethyl imatinib (NDI), 328 plasma samples from 273 patients treated with imatinib were retrospectively analyzed. Imatinib C min and NDI C min were tested, and adverse reactions were recorded. The association between imatinib C min , NDI C min , and serious adverse reactions was evaluated. The C min range of imatinib was 209.5-4950.0 ng/mL, with the mean value and SD of 1491.8 ± 731.4 ng/mL. The C min range of NDI was 80.0-2390.0 ng/mL with the mean value and SD of 610.8 ± 281.5 ng/mL. NDI C min was positively correlated with imatinib C min , whereas the ratio of NDI C min to imatinib C min (NDI C min /imatinib C min ) was negatively correlated with imatinib C min . Univariate logistic regression analysis demonstrated that the treatment objective, daily dose, imatinib C min , NDI C min , and imatinib C min + NDI C min were significantly associated with serious adverse reactions. Multivariate logistic regression analysis showed that NDI C min was an independent risk factor for serious adverse reactions, with a threshold of 665 ng/mL. NDI C min was an independent risk factor for serious adverse reactions, with a threshold of 665 ng/mL. Monitoring NDI C min was beneficial for the rational application of imatinib and individualized treatment of patients with gastrointestinal stromal tumors.

Meta-analysis of improved thoracolumbar interfascial plane block on postoperative analgesia and adverse reactions in patients undergoing lumbar surgery

Meta-analysis of improved thoracolumbar interfascial plane block on postoperative analgesia and adverse reactions in patients undergoing lumbar surgery

Effect of epirubicin combined with docetaxel on inflammatory factors, cytokines, tumor markers, clinical efficacy and adverse reactions in patients with cervical cancer after surgery

Effect of epirubicin combined with docetaxel on inflammatory factors, cytokines, tumor markers, clinical efficacy and adverse reactions in patients with cervical cancer after surgery

Effectiveness and Safety of Chinese Herbal Injections Combined with SOX Chemotherapy Regimens for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.

Background: Randomized controlled trials (RCTs) have demonstrated that combining Chinese herbal injections (CHIs) with oxaliplatin plus tegafur (SOX) chemotherapy regimens improves clinical effectiveness and reduces adverse reactions in patients with advanced gastric cancer (AGC). These RCTs highlight the potential applications of CHIs and their impact on AGC patient prognosis. However, there is insufficient comparative evidence on the clinical effectiveness and safety of different CHIs when combined with SOX. Therefore, we performed a network meta-analysis to rank the clinical effectiveness and safety of different CHIs when combined with SOX chemotherapy regimens. This study aimed to provide evidence for selecting appropriate CHIs in the treatment of patients with AGC. Methods: We searched eight databases from their inception until March 2023. Surface Under the Cumulative Ranking Curve (SUCRA) probability values were used to rank the treatment measures, and the Confidence in Network Meta-Analysis (CINeMA) software assessed the grading of evidence. Results: A total of 51 RCTs involving 3,703 AGC patients were identified. Huachansu injections + SOX demonstrated the highest clinical effectiveness (SUCRA: 78.17%), significantly reducing the incidence of leukopenia (93.35%), thrombocytopenia (80.19%), and nausea and vomiting (95.15%). Shenfu injections + SOX improved Karnofsky's Performance Status (75.59%) and showed a significant reduction in peripheral neurotoxicity incidence (88.26%). Aidi injections + SOX were most effective in reducing the incidence of liver function damage (75.16%). According to CINeMA, most confidence rating results were classified as "low". Conclusion: The combination of CHIs and SOX shows promising effects in the treatment of AGC compared to SOX alone. Huachansu and Shenfu injections offer the greatest overall advantage among the CHIs, while Aidi injections are optimal for reducing the incidence of liver damage. However, further rigorous RCTs with larger sample sizes and additional pharmacological studies are necessary to reinforce these findings.

Significant Effect of Ritodrine Hydrochloride Combined with Magnesium Sulfate for Treatment of Patients with Premature Rupture of Membranes

To investigate the effect of magnesium sulfate combined with ritodrine hydrochloride on maternal and infant outcomes in patients with premature rupture of membranes (PROM), a total of 76 PROM patients admitted to our hospital from July 2021 to July 2022 were selected as the research objects, and they were divided into observation group and experimental group according to the treatment methods of the patients. The observation group consisted of 38 patients who received magnesium sulfate monotherapy, whereas the experimental group received ritodrine hydrochloride in addition to the treatment received by the patients in the observation group. The treatment effects, levels of inflammatory factors, negative emotions, as well as maternal and child outcomes, along with any adverse reactions during the medication, were compared between the two groups. The effective rate of treatment in the observation group was 78.95%, and that in the experimental group was 97.37%. The effective rate in the experimental group was significantly higher than that in the observation group (P < 0.05). The levels of α and IFN-y were significantly lower than those of the observation group (all, P < 0.05); the SAS scores and SDS scores of the experimental group after treatment were significantly lower than those of the observation group (all, P < 0.05). The observation group showed significantly lower uterine contraction inhibition time and postpartum hemorrhage compared to the observation group, along with significantly higher gestational age extension time (all, P <0.05). In terms of neonatal outcomes, the birth weight, Apgar. The scores were significantly higher than those of the observation group, and the incidence of complications was significantly lower than that of the observation group (all, P < 0.05). The incidence of adverse reactions in the observation group was 21.05%, compared to 23.68% in the experimental group. There was no significant difference in the incidence of adverse reactions between the two groups of patients (P > 0.05). Magnesium sulfate combined with ritodrine hydrochloride has a significant effect in the treatment of patients with PROM. The application of the combined program can effectively reduce the inflammatory response of patients, regulate the negative emotions of patients, and improve the maternal and infant outcomes of patients. Moreover, the combined program does not increase the risk of adverse reactions in patients, demonstrating its ideal safety in clinical medication.

Adverse Drug Reactions in Multi-Drug Resistant Tuberculosis Patients, in India, who had received DOTS Plus Treatment along with Home Care and Counselling

Background: Adverse drug reactions are common in MDR-TB patients on treatment. An adverse drug reaction (ADR) is defined as an appreciably harmful or unpleasant reaction resulting from an intervention related to the use of a medicinal product. Revised National Tuberculosis Control Programme used 24-months long Category IV/DOTS Plus regimen for treatment of MDR-TB. The Community Health Department of St. Stephen’s Hospital started an innovative project in 2009, in the form of Home Care for MDR Patients and it concluded with Long-term Follow-up of patients, who had received DOTS Plus Treatment along with Home Care and Counselling (2015). Aims: To study the spectrum, severity and the risk factors for ADRs in MDR-TB patients. Methods: In this retrospective study files of 109 MDR-TB patients who had received treatment along with home care and counselling support, were reviewed. The study was conducted between January to May 2024. Results: Out of 109 MDR TB patients there were 68 (62%) developed one or more ADR. Joint pains 44(40.36%), was the most commonly observed ADR, followed by nausea 29(26.6%) and vomiting 25(22.93%), weakness 23(21.1%), anxiety and depression 16(14.67%), difficulty in breathing 14(12.84%), tremors 13(11.9%), giddiness 11(10.1%), skin rashes 10(9.2%). According to Hartwig Scale mild ADRs were 58.8%, moderate 5.9% and severe 35.3%. Patients who had BMI <18.5 experienced less ADRs with an Odds Ratio =0.22; 95% CI=0.06 to 0.72, p=0.0124. Unemployment was associated with higher number of ADRs OR=3.5; 95% CI=0.99 to 12.29, p=0.05. Sixty-two % MDR TB patients had ADRs. Our treatment outcomes showed 41(60.3) as cured, 24(35.3) died, 2(2.9) defaulted and 1(1.5) failed treatment. This was possible because healthcare teams counselled and provided all possible support to patients 24x7 thus improving adherence to therapy. Conclusion: ADRs occurred in more than half of the cases, with joint pain being the most common. Interventions such as counselling of patients and their family on importance of adherence to drugs at the initiation of treatment, provision of nutritional support, psychological counselling and motivation, instant referral for ADRs and care of patients at referred facilities, help patients not becoming defaulters.

Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study.

Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data. This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION). This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0-23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%). This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and long-term follow-up.

Unraveling Catechol-O-Methyltransferase rs4680 SNP's Role in Patients' Response to Tramadol and Its Adverse Effects: A Pharmacogenetics Insight into Postoperative Pain Management.

Effective postoperative pain management is essential for patient well-being and an efficient healthcare system. Variations in the Catechol O-Methyltransferase (COMT) gene, specifically rs4680, play a crucial role in pain perception and opioid response. This study seeks to elucidate the impact of rs4680 polymorphism on tramadol efficacy and adverse reactions in post-surgical patients. We performed an uncontrolled cohort pharmacogenetics study in which participants underwent postoperative tramadol administration. The frequencies of rs4680 alleles were determined and the association between rs4680 genotypes and the efficacy of tramadol analgesic as pain relief, measured by the Numeric Rating Scale (NRS), was analyzed. Secondary outcomes included tramadol-induced sedation levels, opioid-induced nausea and vomiting, and other adverse effects of tramadol. Data analysis, using IBM SPSS Statistics 23, focused on pain and side effect differences across genotypes, with statistical significance set to p ≤ 0.05. The COMT (rs4680) genotype distribution exhibited a 'G' allele frequency of 41.5% and an 'A' allele frequency of 58.5%, with the AA genotype present in 44% of individuals, adhering to the Hardy-Weinberg equilibrium (p = 0.788). Patients with the AA genotype reported lower pain scores post-tramadol administration across all times examined (p < 0.001), but also experienced statistically significant (p < 0.001) higher incidences of tramadol-induced nausea, vomiting, and sedation. However, GG genotype individuals experienced poor pain relief from tramadol, requiring more supplemental analgesia. These significant findings underscore the critical role of COMT rs4680 polymorphism in response to tramadol and the necessity of a personalized approach to postoperative pain management.

The Design and Application of a New Type of Bed Sheet Restraint Device: A Randomized Controlled Study

Objective: To observe the application effect of the new type of bed sheet restraint device in NICU. Methods: A randomized controlled trial was carried out. A total of 100 patients randomly divided into observation group and control group, with 50 patients in each group. Patients in the observation group used the new type of bed sheet restraint device, while the control group used the conventional restraint device. The restraint-related adverse reaction, restraint time and ICU stay time were compared between the two groups. Results: There was no fall from bed in the two groups of patients. The incidence of the change of skin color, temperature, texture and restraint devices break free, unplanned extubation of the observation group was significantly lower than that of the control group. The restraint time and ICU stay time of the observation group was significantly less than that of the control group. The difference was statistically significant. Conclusion: The new type of bed sheet restraint device can effectively reduce the incidence of restraint-related adverse reactions of patients, and reduce the restraint time and ICU stay time of patients, which is worthy of clinical application.

Assessment of Medication Adherence and Adverse Drug Reactions in Depressive Patients Taking Selective Serotonin Reuptake Inhibitors in Tertiary Care Hospitals in Kerala

Assessment of Medication Adherence and Adverse Drug Reactions in Depressive Patients Taking Selective Serotonin Reuptake Inhibitors in Tertiary Care Hospitals in Kerala

Haemovigilance resources available for everyone: A report from the International Haemovigilance Tools Collaborative Project.

Haemovigilance systems are intended to collect and analyse data, and report findings relating to transfusion complications, such as blood product safety, procedural incidents, and adverse reactions in donors and patients. A common problem among developing haemovigilance programs is the lack of resources and tools available to countries striving to establish or enhance their haemovigilance system. World Health Organization, in collaboration with International Society for Blood Transfusion (ISBT), International Haemovigilance Network and other haemovigilance experts embarked on a Haemovigilance Tools Project to collect and provide materials and resources to assist with the stepwise implementation of haemovigilance. Resources are housed as a virtual compendium on the ISBT website under the Haemovigilance Working Party. These are managed by a subcommittee of the Working Party and are freely available and downloadable to all without requiring ISBT membership.

SUBJECTIVE ANALYSIS OF QUALITY INDICATORS OF MEDICINAL PRODUCTS

The purpose of the study is to assess the quality indicators and side effects of medicinal substances from a subjective point of view. Materials and methods. 40 attending therapeutists, 45 pharmacists and 100 patients were involved in the study at the Department of Pharmaceutical Technologies and Management and the Department of Medical and Biological Physics, the Azerbaijan Medical University in order to assess the quality indicators and side effects of medicinal substances from a subjective point of view. At the first stage, a special survey was used to study which factors, such as efficacy, safety, quality and price of drug, are accepted as the main criteria when prescribing a particular drug in research institutions.Results: Among the surveyed internists, 31 individuals, constituting 77.5% of the participants, emphasized the significance of product quality when prescribing medications. Two pharmacists from the total surveyed mentioned drug-induced side effects affecting the respiratory system. Furthermore, 77.5% of internists engaged in the survey reported that medicinal substances resulted in gastrointestinal side effects not explicitly outlined in the instructions. 88.9% of participating pharmacists noted drug-induced side effects on the gastrointestinal system in patients. Conclusions: The effective resolution of the issue investigated in this study hinges on the practical implementation of modern and enhanced pharmacovigilance methods to monitor the circulation of substandard medicines. This requires fostering a responsible attitude among all stakeholders, including the primary subjects of treatment, towards timely detection and improvement of drug safety. In clinical practice, instances of adverse reactions in patients using medications have frequently been observed. Most commonly, doctors and pharmacists noted similar reactions originating from the gastrointestinal tract, with respiratory system issues reported less frequently. When selecting medications, both doctors and pharmacists prioritize effectiveness, safety, and quality, with cost being of lesser importance.

Adverse clinical outcomes associated with drug-related hospitalizations in people with dementia

ABSTRACTBackgroundThis study aimed to determine the clinical impact associated with adverse drug reactions (ADRs) in patients with dementia.Research design and methodsThis case-control, propensity score-matched study utilized administrative data of people with dementia admitted to major public hospitals in Tasmania, Australia, from July 2010 to December 2019.ResultsAcute renal failure constituted the most common ADR. The length of hospital stay was greater for people with an ADR index admission, versus non-ADR index admission (median [IQR]: 9 [4–18] versus 6 [2–12]; p < 0.001). In-hospital mortality and combined in-hospital and post-hospital mortality within 30, 60 and 90 days were higher for those whose index admission was ADR-related (in-hospital: HR 1.40, 95% CI 1.11–1.77, p-value <0.001; 30 days: HR 1.25, 95% CI 1.05–1.49, p-value <0.001; 60 days: HR 1.27, 95% CI 1.08–1.49, p-value <0.001; 90 days: HR 1.29, 95% CI 1.10–1.50, p-value <0.001). Subsequent ADR admission within 30, 60 and 90 days of index discharge was 9 to 10 times greater for people with dementia (30 days: OR 10.0, 95% CI 6.04–16.8, p-value <0.001; 60 days: OR 8.96, 95% CI 5.57–14.4, p-value <0.001; 90 days: OR 9.31, 95% CI 5.79–14.9, p-value <0.001).ConclusionSafe prescribing and vigilant monitoring of ADRs is pivotal to mitigate adverse outcomes in people with dementia.

Validation of a popsicle as a clear fluid to abbreviate preoperative fasting

Background & AimsThis study is based on the development and validation of a popsicle to reduce preoperative fasting time. MethodsThe study was carried out in two stages, pre-clinical and clinical validation. The first stage consisted of producing a water-based, fat-free, high-calorie fruit-flavored popsicle, characterized by proximal composition and sensory analysis. In the second stage, clinical validation was performed in patients aged between 18 and 65 years before elective surgery, evaluating the incidence of aspiration during anesthesia and the patient's experience in relation to hunger, thirst, anxiety and palatability of the popsicle. ResultsThe results of the study showed that the use of popsicle two hours before the surgical procedure did not cause any adverse reaction in patients and in the anesthetic procedure. Furthermore, the full acceptability of the product by the participants and the control of thirst and satiety during the preoperative period were observed. ConclusionsThe present study showed that with the use of popsicles it was possible to reduce safely the preoperative fasting time to up to two hours before the surgical procedure.

Ampicillin-Sulbactam-Induced Liver Injury in a Pediatric Patient

Drug-induced liver injury (DILI) is a rare adverse drug reaction (ADR) in pediatric patients and limited reports exist examining ampicillin-sulbactam-induced liver injury. This report summarizes a 12-year-old male who received ampicillin-sulbactam and subsequently developed liver injury characterized by elevated serum aminotransferases and bilirubin. Ampicillin-sulbactam was subsequently discontinued and the patient’s liver function tests (LFTs) rapidly improved. This report describes the rare adverse reaction of ampicillin-sulbactam-induced liver injury.

Efficacy of Systematic Nursing Combined with Lianzhi Xiaoyan Capsule on Clinical Outcome of Emergency Intravenous Infusion in Patients with Acute Gastroenteritis

This study aimed to explore the efficacy of systematic nursing combined with Lianzhi Xiaoyan capsule on clinical efficacy and the incidence of adverse reactions due to emergency intravenous infusion in patients with acute gastroenteritis. The patients were divided into a control group, comprising patients who received conventional Western medicine treatment and routine emergency nursing, and an observation group, comprising patients who received conventional Western medicine treatment and routine emergency nursing combined with Lianzhi Xiaoyan capsules. The total effective rates among patients in the observation group were higher than those among patients in the control group (P &lt; 0.05). The durations of fever, abdominal pain, diarrhea, nausea, and vomiting among patients in the observation group were shorter than those among patients in the control group. High-sensitivity C-reactive protein, interleukin-6, and CD8+ levels among patients in the observation group were lower than those among patients in the control group. The incidences of adverse reactions during intravenous infusion were lower, and patient satisfaction with nursing care was higher among patients in the observation group than among those in the control group. Systematic nursing combined with Lianzhi Xiaoyan capsules has significant clinical efficacy and can reduce emergency intravenous infusion-related adverse reactions in patients with acute gastroenteritis.

Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer.

The relationship between single nucleotide polymorphisms (SNPs) at various loci and adverse drug reactions (ADRs) in patients with gynecologic cancer receiving platinum-based chemotherapy (PPCT) remains unexplored. This research aimed to investigate the correlation between SNPs at several loci (e.g., GSTP1 rs1695, MTHFR rs1801133, XPC rs2228001, TP53 rs1042522, and ERCC1 rs3212986) and ADRs in patients with gynecologic cancer receiving PPCT. A total of 244 patients with gynecologic cancer who received first-line PPCT were included in this retrospective study. Blood fluorescence quantitative polymerase chain reaction was used to detect genotypes. Logistic regression, Pearson's Chi-square test, and Fisher's exact test were used to explore the correlations between these SNPs and the occurrence of ADRs. The logistic regression results showed that different genotypes of the five genes had no statistical significance in the overall grade greater than or equal to 3 ADRs. The results of Pearson's Chi-square test showed the same results. On specific adverse reactions, we found that the rs1042522 GG genotype significantly increased the risk of grade greater than or equal to 3 leucopenia compared with the CG and the CC genotypes (p = 0.002). The rs1695 AG genotype showed higher correlation for grade greater than or equal to 3 neutropenia (p = 0.020). The rs2228001 CC genotype also had a higher risk for grade greater than or equal to 3 neutropenia (p = 0.003). This study found that whereas the overall grade greater than or equal to 3 adverse reactions in patients with gynecologic cancer receiving PPCT were not associated with SNPs, specific SNPs (rs1042522 GG, rs1695 AG, and rs2228001 CC) were linked to higher risks of leucopenia and neutropenia, indicating their potential as predictors of hematotoxicity in PPCT-treated patients with gynecologic cancer.